# SANTA CRUZ BIOTECHNOLOGY, INC.

# IGFBP1 (H-3): sc-25257



## BACKGROUND

The Insulin-like growth factor-binding proteins (IGFBPs), a family of homologous proteins that have co-evolved with the IGFs, serve not only as shuttle molecules for the soluble IGFs, but also confer a level of regulation to the IGF signaling system. Physical association of the IGFBPs with IGF influences the bio-availability of the growth factors, and their concentration and distribution in the extracellular environment. The IGFBPs also appear to have biological activity independent of the IGFs. Seven IGFBPs have been described, each differing in their tissue distribution, half-lives and modulation of IGF interactions with their receptors. IGFBP1 is negatively regulated by Insulin production. The IGFBP1 gene is expressed at a high level during fetal liver development and in response to nutritional changes and diabetes. IGFBP2, which may function as a chaperone, escorting IGFs to their target tissues, is expressed in several human tissues including fetal eye and fetal brain. IGFBP3, the most abundant IGFBP, is complexed with roughly 80% of the serum IGFs. Both IGFBP3 and IGFBP4 are released by dermal fibroblasts in response to incision injury. IGFBP5 is secreted by myoblasts and may play a key role in muscle differentiation. IGFBP6 differs from other IGFBPs in having the highest affinity for IGF-II. Glycosylated human IGFBP6 is expressed in Chinese hamster ovary (CHO) cells, whereas non-glycosylated recombinant human IGFBP-6 is expressed in E. coli. IGFBP7, a secreted protein that binds both IGF-I and IGF-II with a relatively low affinity, stimulates prostacyclin production and may also function as a growth-suppressing factor.

## CHROMOSOMAL LOCATION

Genetic locus: IGFBP1 (human) mapping to 7p12.3.

#### SOURCE

IGFBP1 (H-3) is a mouse monoclonal antibody raised against amino acids 121-140 of IGFBP1 of human origin.

### PRODUCT

Each vial contains 200  $\mu g$  lgG\_{2a} kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## **APPLICATIONS**

IGFBP1 (H-3) is recommended for detection of IGFBP1 of human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:500), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for IGFBP1 siRNA (h): sc-39584, IGFBP1 shRNA Plasmid (h): sc-39584-SH and IGFBP1 shRNA (h) Lentiviral Particles: sc-39584-V.

Molecular Weight of IGFBP1: 36 kDa.

Positive Controls: Hep G2 cell lysate: sc-2227.

#### STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## DATA





 $\mathsf{IGFBP1}\xspace$  (H-3): sc-25257. Western blot analysis of human recombinant  $\mathsf{IGFBP1}\xspace$ 

IGFBP1 (H-3): sc-25257. Immunoperoxidase staining of formalin fixed, paraffin-embedded human renal cancer showing cytoplasmic staining of tumor cells. Kindly provided by The Swedish Human Protein Atlas (HPA) program.

#### SELECT PRODUCT CITATIONS

- Shin, J.C., et al. 2003. Expression of Insulin-like growth factor-II and Insulin-like growth factor binding protein-1 in the placental basal plate from pre-eclamptic pregnancies. Int. J. Gynaecol. Obstet. 81: 273-280.
- Sugita, S., et al. 2011. IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. Histopathology 58: 729-738.
- Gao, H., et al. 2012. Maternal protein restriction regulates IGF2 system in placental labyrinth. Front. Biosci. 4: 1434-1450.
- Wang, X.B., et al. 2018. Role of osteopontin in decidualization and pregnancy success. Reproduction 155: 423-432.
- Bak, D.H., et al. 2018. Human umbilical cord blood mesenchymal stem cells engineered to overexpress growth factors accelerate outcomes in hair growth. Korean J. Physiol. Pharmacol. 22: 555-566.
- 6. Shukla, V., et al. 2019. Inhibition of TPPP3 attenuates  $\beta$ -catenin/NF $\kappa$ B/ Cox-2 signaling in endometrial stromal cells and impairs decidualization. J. Endocrinol. 240: 417-429.
- Tao, A., et al. 2021. Effect of lycopene on oral squamous cell carcinoma cell growth by inhibiting IGF1 pathway. Cancer Manag. Res. 13: 723-732.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

### PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.